UPDATE: Denali Phase 1/2 Study Of DNL310 Showed 'Sustained normalization and further decreased levels of CSF glycosaminoglycan heparan sulfate'; Was Generally Well Tolerated With Safety Profile Consistent With Other Enzyme Replacement Therapies